智通财经APP获悉，辉瑞(PFE.US)公布了好于预期的2025年第三季度业绩，同时上调了全年盈利预期。该公司表示，持续推进的成本削减措施 帮助弥补了销售增长放缓带来的压力，这也为其竞购减肥药初创公司Metsera(MTSR.US)提供了资金支持。 财报显示，辉瑞Q3营收同比下降6%至166.54亿美元，好于分析师普遍预期的165亿美元;调整后的净利润为49.49亿美元，同比下降18%;调整后的 每股收益为0.87美元，好于分析师普遍预期的0.64美元。 | ($ in millions, except per share | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | amounts) | Third-Quarter | | | | Nine Months | | | | 2025 | 2024 | % Change | 2025 | 2024 | % Change | | Revenues | $ 16,654 | $ 17,702 | (6%) | $ 45,022 | $ 45,864 | (2%) | | Reported(3) ...

TESLA WATCH: Elon Musk Pay Deal In Focus Metsera (MTSR) called Pfizer's (PFE) claims "nonsense" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk (NVO) over their proposed merger. The company's statement is the most recent salvo in a battle that began last week when Novo made an unsolicited $6.5 billion bid to buy Metsera. Metsera, an obesity-focused biotech company, had already agreed to a smaller $4.9 billion deal with Pfizer. Pfizer is suing the duo, claiming Novo is trying to st ...

Denmark's Novo Nordisk said on Monday it is confident that its proposed takeover of U.S. drugmaker Metsera does not raise any antitrust issues. ...

A Pfizer logo is displayed at a research facility in the La Jolla neighborhood of San Diego, California, U.S., Sept. 30, 2025.Pfizer on Monday said it filed a second lawsuit against Novo Nordisk and Metsera, alleging that the Danish drugmaker's attempt to outbid Pfizer to acquire the obesity biotech is anticompetitive. Pfizer alleges that Ozempic maker Novo Nordisk's proposed acquisition of Metsera would help it maintain its dominant position in the blockbuster obesity market by eliminating a smaller potent ...

Key TakeawaysNovo Nordisk (NVO) has launched an unsolicited bid valued at up to $9 billion for obesity-drug developer Metsera (MTSR), aiming to outbid Pfizer's (PFE) existing agreement of up to $7.3 billion.Metsera's board has deemed Novo Nordisk's offer a "superior proposal," triggering a four-business-day window for Pfizer to renegotiate its terms, amidst Pfizer's accusations of antitrust violations and breach of contract.Novo Nordisk has vehemently denied Pfizer's claims, stating that Pfizer is "fundamen ...

Lawsuit says the proposed merger of the weight-loss drugmakers could kill off a smaller competitor. ...

Pfizer Files Federal Antitrust Claims in Second Lawsuit Against Metsera, its Controlling Stockholders and Novo Nordisk Share NEW YORK--(BUSINESS WIRE)--Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of Delaware. The lawsuit asserts that Novo Nordisk's recent proposal to acquire Metsera constitutes an anticompetitive action by Novo Nordisk to protect its dominant mark ...

We recently published 10 Stocks With Easy 20-40% Gains. Metsera Inc. (NASDAQ:MTSR) is one of the last week's best-performing stocks. Metsera saw its share prices jump by 20 percent week-on-week as investors gobbled up shares amid a billion-dollar bidding war between two pharmaceutical giants racing to gain a larger foothold in the booming weight-loss industry. This followed Novo Nordisk’s confirmation late last week that it submitted a new $8.5 billion offer to acquire Metsera Inc. (NASDAQ:MTSR), which w ...

同时，辉瑞宣布已向特拉华州 衡 平法院（ De l awa r e Co urt o f Cha nc e r y ） 提起诉讼，起诉Me ts e r a及 其董事会和Nov o Nor dis k。该诉讼声称，由于Me ts e r a违反了辉瑞和Me ts e r a之间的合并协议规定的义务，因此违反了合同、违 反了信托责任和侵权干涉合同。 辉瑞声称根据合并协议的条款，诺和诺德的报 价不符合" Su pe ri o r Compa n y Pr o po s a l "的条件，包括因为相对 于辉瑞的交易 ，考虑到提案的重大监管风险，诺和诺德的交易不太可能按照拟议的条款完成。相比之下，今天美国联邦贸易委员 会根据经修订的19 76年《哈特-斯科特-罗迪诺反垄断改进法案》，就辉瑞即将收购Me ts e r a一事，提前终止了等待期。辉瑞收购 Me ts e r a的所有监管批准均已获得，辉瑞准备在11月1 3日的Me ts e r a股东大会后不久完成交易。 正如诉讼中所述，拟议的诺和诺德交易是一家具有市场主导地位的公司压制竞争的非法企图，并使用了一种前所未有的结构，旨 在故意逃避反垄断审查。Me ts e ...

Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera. ...